Literature DB >> 29242082

Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Chelsea B Polis1, Sharon L Achilles2, Zdenek Hel3, Janet P Hapgood4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242082      PMCID： PMC5828886          DOI： 10.1016/j.contraception.2017.12.003

Source DB:  PubMed          Journal:  Contraception        ISSN： 0010-7824            Impact factor:   3.375


× No keyword cloud information.
  78 in total

1.  Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.

Authors:  Vera Halpern; Stephanie L Combes; Laneta J Dorflinger; Debra H Weiner; David F Archer
Journal:  Contraception       Date:  2013-07-12       Impact factor: 3.375

2.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

3.  Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion.

Authors:  Charles Morrison; Raina N Fichorova; Chris Mauck; Pai-Lien Chen; Cynthia Kwok; Tsungai Chipato; Robert Salata; Gustavo F Doncel
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

4.  Medroxyprogesterone acetate in human serum.

Authors:  M Mathrubutham; K Fotherby
Journal:  J Steroid Biochem       Date:  1981-08       Impact factor: 4.292

5.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

6.  Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.

Authors:  Sinaye Ngcapu; Lindi Masson; Sengeziwe Sibeko; Lise Werner; Lyle R McKinnon; Koleka Mlisana; Muki Shey; Natasha Samsunder; Salim Abdool Karim; Quarraisha Abdool Karim; Jo-Ann S Passmore
Journal:  J Reprod Immunol       Date:  2015-04-22       Impact factor: 4.054

7.  Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.

Authors:  Holly M Burke; Monique P Mueller; Catherine Packer; Brian Perry; Leonard Bufumbo; Daouda Mbengue; Bocar Mamadou Daff; Anthony Mbonye
Journal:  Contraception       Date:  2014-01-21       Impact factor: 3.375

8.  Contraceptive efficacy and safety of DMPA-SC.

Authors:  J Jain; A J Jakimiuk; F R Bode; D Ross; A M Kaunitz
Journal:  Contraception       Date:  2004-10       Impact factor: 3.375

9.  Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.

Authors:  Shinichi Sasagawa; Yutaka Shimizu; Hideaki Kami; Takashi Takeuchi; Shizuka Mita; Kazunori Imada; Shigeaki Kato; Kiyoshi Mizuguchi
Journal:  Steroids       Date:  2007-10-22       Impact factor: 2.668

10.  Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.

Authors:  N E Quispe Calla; R D Vicetti Miguel; P N Boyaka; L Hall-Stoodley; B Kaur; W Trout; S D Pavelko; T L Cherpes
Journal:  Mucosal Immunol       Date:  2016-03-23       Impact factor: 7.313
View more
  12 in total

1.  HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.

Authors:  Renee Heffron; Randy Stalter; Maria Pyra; Kavita Nanda; David W Erikson; Florian Hladik; Steven W Blue; Nicole L Davis; Nelly Mugo; Athena P Kourtis; Jairam R Lingappa; Jared M Baeten
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

2.  Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion.

Authors:  Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Kristen M Aceves; Angelo Torres; Thomas L Cherpes
Journal:  Contraception       Date:  2019-07-11       Impact factor: 3.375

Review 3.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

4.  The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.

Authors:  Roslyn M Ray; Michelle F Maritz; Chanel Avenant; Michele Tomasicchio; Sigcinile Dlamini; Zephne van der Spuy; Janet P Hapgood
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

5.  Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.

Authors:  Renee Heffron; Sharon L Achilles; Laneta J Dorflinger; Janet P Hapgood; James Kiarie; Chelsea B Polis; Petrus S Steyn
Journal:  Contraception       Date:  2018-12-18       Impact factor: 3.375

6.  Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.

Authors:  Michelle F Maritz; Roslyn M Ray; Alexis J Bick; Michele Tomasicchio; John G Woodland; Yashini Govender; Chanel Avenant; Janet P Hapgood
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

7.  Exogenous sex steroids regulate genital epithelial barrier function in female rhesus macaques.

Authors:  Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Linda Fritts; Christopher J Miller; Kristen M Aceves; Thomas L Cherpes
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

8.  Task-shifting the provision of DMPA-SC in the DR Congo: Perspectives from two different groups of providers.

Authors:  Julie H Hernandez; Pierre Akilimali; Annie Glover; Rebecca Emel; Albert Mwembo; Jane Bertrand
Journal:  Contraception       Date:  2018-07-18       Impact factor: 3.375

9.  The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor.

Authors:  Michele Tomasicchio; Malika Davids; Anil Pooran; Grant Theron; Liezel Smith; Lynn Semple; Richard Meldau; Janet Patricia Hapgood; Keertan Dheda
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

10.  Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.

Authors:  Janet P Hapgood
Journal:  AIDS Res Hum Retroviruses       Date:  2020-01-22       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.